Co-impairment of autonomic and glucagon responses to insulin-induced hypoglycemia in dogs with naturally occurring insulin-dependent diabetes mellitus

• Published in: American journal of physiology: endocrinology and metabolism Vol. 319; no. 6; p. E1074
• Main Authors: Gilor, Chen, Duesberg, Cynthia, Elliott, Denise A, Feldman, Edward C, Mundinger, Thomas O, Taborsky, Jr, Gerald J, Nelson, Richard W, Havel, Peter J
• Format: Journal Article
• Language: English
• Published: United States 01-12-2020
• Subjects: Animals; Autonomic Nervous System - drug effects; Blood Glucose - metabolism; C-Peptide - metabolism; Diabetes Mellitus, Type 1 - metabolism; Diabetes Mellitus, Type 1 - veterinary; Dog Diseases - metabolism; Dogs; Epinephrine - blood; Glucagon - pharmacology; Glucagon-Secreting Cells - drug effects; Glucose Clamp Technique; Hypoglycemia - chemically induced; Hypoglycemia - metabolism; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells - drug effects; Norepinephrine - blood; Pancreatic Polypeptide - metabolism; norepinephrine; epinephrine; pancreatic polypeptide; sympathoadrenal; C-peptide
• ISSN: 1522-1555
• DOI: 10.1152/ajpendo.00379.2020

This study aimed to investigate the contributions of two factors potentially impairing glucagon response to insulin-induced hypoglycemia (IIH) in insulin-deficient diabetes:
) loss of paracrine disinhibition by intra-islet insulin and
) defects in the activation of the autonomic inputs to the islet. Plasma glucagon responses during hyperinsulinemic-hypoglycemic clamps ([Formula: see text]40 mg/dL) were assessed in dogs with spontaneous diabetes (
= 13) and in healthy nondiabetic dogs (
= 6). Plasma C-peptide responses to intravenous glucagon were measured to assess endogenous insulin secretion. Plasma pancreatic polypeptide, epinephrine, and norepinephrine were measured as indices of parasympathetic and sympathoadrenal autonomic responses to IIH. In 8 of the 13 diabetic dogs, glucagon did not increase during IIH (diabetic nonresponder [DMN]; ∆ = -6 ± 12 pg/mL). In five other diabetic dogs (diabetic responder [DMR]), glucagon responses (∆ = +26 ± 12) were within the range of nondiabetic control dogs (∆ = +27 ± 16 pg/mL). C-peptide responses to intravenous glucagon were absent in diabetic dogs. Activation of all three autonomic responses were impaired in DMN dogs but remained intact in DMR dogs. Each of the three autonomic responses to IIH was positively correlated with glucagon responses across the three groups. The study conclusions are as follows:
) Impairment of glucagon responses in DMN dogs is not due to generalized impairment of α-cell function.
) Loss of tonic inhibition of glucagon secretion by insulin is not sufficient to produce loss of the glucagon response; impairment of autonomic activation is also required.
) In dogs with major β-cell function loss, activation of the autonomic inputs is sufficient to mediate an intact glucagon response to IIH.
In dogs with naturally occurring, insulin-dependent (C-peptide negative) diabetes mellitus, impairment of glucagon responses is not due to generalized impairment of α-cell function. Loss of tonic inhibition of glucagon secretion by insulin is not sufficient, by itself, to produce loss of the glucagon response. Rather, impaired activation of the parasympathetic and sympathoadrenal autonomic inputs to the pancreas is also required. Activation of the autonomic inputs to the pancreas is sufficient to mediate an intact glucagon response to insulin-induced hypoglycemia in dogs with naturally occurring diabetes mellitus. These results have important implications that include leading to a greater understanding and insight into the pathophysiology, prevention, and treatment of hypoglycemia during insulin treatment of diabetes in companion dogs and in human patients.